Literature DB >> 33185660

Characteristics of adrenocortical carcinoma associated with Lynch Syndrome.

Marta Domènech1,2, Elia Grau1,3, Ares Solanes1,3, Angel Izquierdo1,4,5, Jesús Del Valle1, Cristina Carrato6, Marta Pineda1,7, Nuria Dueñas1,7, Magda Pujol8, Conxi Lázaro1,7, Gabriel Capellà1,7, Joan Brunet1,3,7, Matilde Navarro1,3,7.   

Abstract

CONTEXT: Lynch syndrome (LS) is the most common inherited colorectal and endometrial cancer syndrome, caused by germline mutations in DNA mismatch repair (MMR) genes. It is also characterized by an increased risk of other tumours with lower prevalence, such as adrenal cortical carcinoma (ACC), an endocrine tumour with an incidence of < two cases/million individuals/year. Most ACC developed during childhood are associated with hereditary syndromes. In adults this association is not as well established as in children. Previous studies showed a 3.2% prevalence of LS among patients with ACC. EVIDENCE ADQUISITION: The objective of this study is to determine the prevalence of ACC in a Spanish LS cohort and their molecular and histological characteristics. This retrospective study includes 634 patients from 220 LS families registered between 1999 and 2018. EVIDENCE SYNTHESIS: During the follow-up three patients were diagnosed with ACC (0.47%), all were carriers of a MSH2 germline mutation. The three ACC patients presented loss of expression of MSH2 and MSH6 proteins. One tumour analysis showed loss of heterozygosity of the MSH2 wildtype allele. Our findings support previous data which considered ACC as a LS spectrum tumour.
CONCLUSION: MMR protein immunohistochemistry screening could be an efficient strategy to detect LS in patients with ACC.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Lynch syndrome; adrenocortical carcinoma; molecular characteristics

Year:  2020        PMID: 33185660     DOI: 10.1210/clinem/dgaa833

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Adrenocortical carcinoma: Pediatric aspects (Review).

Authors:  Florica Sandru; Răzvan-Cosmin Petca; Mara Carsote; Aida Petca; Mihai Cristian Dumitrascu; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2022-02-16       Impact factor: 2.447

Review 2.  Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging.

Authors:  Alfred King-Yin Lam
Journal:  Biomedicines       Date:  2021-02-10

Review 3.  Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?

Authors:  Camilo Jimenez; Gustavo Armaiz-Pena; Patricia L M Dahia; Yang Lu; Rodrigo A Toledo; Jeena Varghese; Mouhammed Amir Habra
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

Review 4.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Authors:  Ozgur Mete; Lori A Erickson; C Christofer Juhlin; Ronald R de Krijger; Hironobu Sasano; Marco Volante; Mauro G Papotti
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 4.056

Review 5.  Recent advances in Lynch syndrome.

Authors:  Xi Li; Guodong Liu; Wei Wu
Journal:  Exp Hematol Oncol       Date:  2021-06-12

6.  An integrative pan-cancer analysis reveals the oncogenic role of mutS homolog 6 (MSH6) in human tumors.

Authors:  Haibo Zhan; Fengbo Mo; Qiang Xu; Song Wang; Bin Zhang; Xuqiang Liu; Min Dai; Hucheng Liu
Journal:  Aging (Albany NY)       Date:  2021-12-07       Impact factor: 5.682

Review 7.  Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors.

Authors:  Qiyang Shen; Xingyu Liu; Wei Li; Xu Zhao; Tao Li; Kai Zhou; Jianfeng Zhou
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.